Search

The Korean Society of Infectious Diseases has been regularly developing guidelines for adult immunization since 2007. In 2023, the guidelines for the following seven vaccines were revised: influenza, herpes zoster, pneumococcal, tetanus-diphtheria-pertussis (Tdap), human papillomavirus (HPV), meningococcal, and rabies vaccines. For the influenza vaccine, a recommendation for enhanced vaccines for the elderly was added. For the herpes zoster vaccine, a recommendation for the recombinant zoster vaccine was added. For the pneumococcal vaccine, the current status of the 15-valent pneumococcal conjugate vaccine and 20-valent PCV was described. For the Tdap vaccine, the possibility of using Tdap instead of tetanus-diphtheria vaccine was described. For the HPV vaccine, the expansion of the eligible age for vaccination was described. For the meningococcal vaccine, a recommendation for the meningococcal B vaccine was added. For the rabies vaccine, the number of pre-exposure prophylaxis doses was changed. This manuscript documents the summary and rationale of the revisions for the seven vaccines. For the vaccines not mentioned in this manuscript, the recommendations in the 3rd edition of the Vaccinations for Adults textbook shall remain in effect. [ABSTRACT FROM AUTHOR]

배경: The recombinant zoster vaccine (RZV) has demonstrated high vaccine efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA) in 2 phase 3 clinical trials (ZOE-50, NCT01165177; ZOE 70, NCT01165229). VE persisted up to year (Y)2 in the interim analysis of the extension study (ZOSTER-049, NCT02723773). Here, we describe the interim analysis for Y4 of the extension study. Understanding VE persistence and long-term protection against HZ can help optimize RZV use in adults ≥50 YOA. 방법: The study design is detailed in Fig. 1. Primary objective included VE against HZ during ZOSTER-049. Secondary objectives included VE against HZ from 1 month post-dose 2 in the ZOE-50/-70 studies until the end of Y4 of ZOSTER-049 (Y10 post-vacci- nation), persistence of vaccine-induced humoral immunogenicity in terms of anti-glycoprotein E (gE) antibody and cell-mediated immune response in terms of frequency of gE-specific CD4[2+] T-cells and safety. VE analysis for ZOSTER-049 used historical control estimates from the ZOE-50/-70 placebo groups. 결과: ZOSTER-049 enrolled 7,413 participants and 7,277 were included in VE analyses (Fig. 2). During 4 years of follow-up in ZOSTER-049, overall VE against HZ was 81.6% (95% confidence interval [CI]: 75.2-86.6). From 1 month post-dose 2 in ZOE-50/-70 until Y4 of ZOSTER-049, overall VE was 89.0% (95% CI: 85.6-91.3). In ZOSTER-049, anti-gE antibody concentrations persisted >5 times above pre-vaccination up to Y10 post-vaccination (Fig. 3A). Frequency of gE-specific CD4[2+] T-cells remained above pre-vaccination from Y6 to Y10 post-vaccination (Fig. 3B). No safety signals were identified until the end of ZOSTER-049 Y4. 결론: VE against HZ and immune responses to RZV remained high until the end of the observation period for this Y4 interim analysis, suggesting sustained clinical benefit of RZV in adults ≥50 YOA for at least 10 years after vaccination. RZV safety profile remained clinically acceptable. [ABSTRACT FROM AUTHOR]

This survey investigated Korean physician attitudes toward the herpes zoster (HZ) vaccine. A total of 400 physicians answered a self-reported questionnaire. Most physicians knew that HZ poses a significant socioeconomic burden and had good know ledge about HZ and its vaccine. Physicians who did not recommend HZ vaccine were concerned about costs (90.7%, 78/86) and doubted the effectiveness of the vaccine (58.1%, 50/86). Patient demand had a profound effect on physicians decisions; 84.9% (73/86) of them who said not recommending HZ vaccine reported that they would provide the vaccine upon patient request. In conclusion, educational initiatives should be targeted toward both physicians and patients. [ABSTRACT FROM AUTHOR]

To develop a clinical practice guideline for vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), the Korean College of Rheumatology and the Korean Society of Infectious Diseases developed a clinical practice guideline according to the clinical practice guideline development manual. Since vaccination is unlikely to cause AIIRD or worsen disease activities, required vaccinations are recommended. Once patients are diagnosed with AIIRD, treatment strategies should be established and, at the same time, monitor their vaccination history. It is recommended to administer vaccines when the disease enters the stabilized stage. Administering live attenuated vaccines in patients with AIIRD who are taking immunosuppressants should be avoided. Vaccination should be considered in patients with AIIRD, prior to initiating immunosuppressants. It is recommended to administer influenza, Streptococcus pneumoniae, hepatitis A, hepatitis B, herpes zoster, measlesmumps- rubella virus, human papillomavirus, and tetanus-diphtheria-pertussis vaccines in patients with AIIRD; such patients who planned to travel are generally recommended to be vaccinated at the recommended vaccine level of healthy adults. Those who live in a household with patients with AIIRD and their caregivers should also be vaccinated at levels that are generally recommended for healthy adults. [ABSTRACT FROM AUTHOR]